Hiroaki Kusunose

Hiroaki Kusunose

Auto-generated profile, based on publicly available information

Hiroaki Kusunose

Department of Gastroenterology, Sendai City Medical Center, Sendai, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2020 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
YKYoshihide Kanno
Yoshihide Kanno
SKShinsuke Koshita
Shinsuke Koshita
TOTakahisa Ogawa
Takahisa Ogawa
HKHiroaki Kusunose
Hiroaki Kusunose
KMKaori Masu
Kaori Masu
KIKei Ito
Kei Ito
The aim of this study was to evaluate outcomes of inside plastic stents (iPSs) versus those of metal stents (MSs) for treating unresectable perihilar malignant obstructions. For all patients who underwent endoscopic suprapapillary placement of iPS(s) or MS(s) as the first permanent biliary drainage for unresectable malignant perihilar obstructions between January 2014 and August 2019, clinical outcomes using iPSs (n=20) and MSs (n=85), including clinical efficacy, adverse events, and time to recurrence of biliary obstruction (RBO), were retrospectively evaluated. There were no differences in clinical effectiveness (95% for the iPS group vs. 92% for the MS group, p=1.00). Procedure-related adverse events, including pancreatitis, acute cholangitis, acute cholecystitis, and death, were observed for 8% of the MS group, although no patient in the iPS group developed such adverse events. The median time to RBO was 561 days (95% confidence interval, 0-1,186 days) for iPSs and 209 days (127-291 days) for MSs, showing a significant difference (p=0.008). s Time to RBO after iPS placement was significantly longer than that after MS placement. IPSs, which are removable, unlike MSs, were an acceptable option.

1 January 2022 in Pancreatology
Verified
Journal Article
Closed access
TSToshitaka Sakai
Toshitaka Sakai
SKShinsuke Koshita
Shinsuke Koshita
YKYoshihide Kanno
Yoshihide Kanno
TOTakahisa Ogawa
Takahisa Ogawa
HKHiroaki Kusunose
Hiroaki Kusunose
KIKei Ito
Kei Ito

15 December 2019 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
YKYoshihide Kanno
Yoshihide Kanno
FKFumisato Kozakai
Fumisato Kozakai
SKShinsuke Koshita
Shinsuke Koshita
TOTakahisa Ogawa
Takahisa Ogawa
HKHiroaki Kusunose
Hiroaki Kusunose
KIKei Ito
Kei Ito
Background/Aims: This study was conducted to evaluate the outcomes of endoscopic-ultrasound-guided gallbladder drainage (EUS-GBD) using traditional biliary stents without lumen-apposing stents and to determine technical issues. Materials and Methods: All 18 patients who underwent EUS-GBD at our center between 2012 and 2018 were evaluated. After the clinical outcomes (including technical success, clinical effectiveness, adverse events, and recurrence) were analyzed, technical countermeasures for problems extracted from the analysis were developed. Results: The rates of technical success, clinical effectiveness, severe adverse event occurrence, and recurrence of acute cholecystitis were 94% (17/18), 88% (15/17), 6% (1/18, massive bile leakage), and 27% (4/15), respectively. Distal gastrectomy causing scope instability, the non-swollen gallbladder, and double pigtail stent use caused technical difficulties. A fully covered metal stent (fcMS) should be placed in a shallow position so that it does not wedge into the opposite site. When the puncture route involves the gastric wall, the proximal portion of an fcMS located in the stomach can migrate toward the abdominal cavity. Conclusion: Although the clinical outcomes of EUS-GBD were relatively favorable, several technical issues related specifically to EUS-GBD were observed. Technical countermeasures would improve the outcomes.

30 May 2021 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
YKYoshihide Kanno
Yoshihide Kanno
TOTetsuya Ohira
Tetsuya Ohira
YHYoshihiro Harada
Yoshihiro Harada
SKShinsuke Koshita
Shinsuke Koshita
TOTakahisa Ogawa
Takahisa Ogawa
KIKei Ito
Kei Ito
The aim of this study was to evaluate the safety of sedation with propofol as an alternative to benzodiazepine drugs in outpatient endoscopy. In this prospective study, examinees who underwent outpatient endoscopy under propofol sedation and submitted a nextday questionnaire with providing informed consent were evaluated. Periprocedural acute responses, late adverse events within 24 hours, and examinee satisfaction were evaluated. Among the 4,122 patients who received propofol in the 17,978 outpatient-based endoscopic examinations performed between November 2016 and March 2018, 2,305 eligible examinees (esophagogastroduodenoscopy for 1,340, endoscopic ultrasonography for 945, and total colonoscopy for 20) were enrolled, and their responses to a questionnaire were analyzed. The mean propofol dose was 69.6±24.4 mg (range, 20-200 mg). Diazepam, midazolam, and/or pentazocine in combination with propofol was administered to 146 examinees. Mild oxygen desaturation was observed in 59 examinees (2.6%); and mild bradycardia, in 2 (0.09%). Other severe reactions or late events did not occur. After eliminating 181 invalid responses, 97.7% (2,065/2,124) of the patients desired propofol sedation in future examinations. Propofol sedation was found to be safe-without severe adverse events or accidents-for outpatient endoscopy on the basis of the patients' next-day self-evaluation. Given the high satisfaction level, propofol sedation might be an ideal tool for painless endoscopic screening.


30 September 2024 in Clinical Endoscopy
Verified
Journal Article
Open access
FKFumisato Kozakai
Fumisato Kozakai
YKYoshihide Kanno
Yoshihide Kanno
SKShinsuke Koshita
Shinsuke Koshita
TOTakahisa Ogawa
Takahisa Ogawa
HKHiroaki Kusunose
Hiroaki Kusunose
KIKei Ito
Kei Ito
Background/Aims: Endoscopic biliary drainage using self-expandable metallic stents (SEMSs) for malignant biliary strictures occasionally induces acute cholecystitis (AC). This study evaluated the efficacy of prophylactic gallbladder stents (GBS) during SEMS placement.Methods: Among 158 patients who underwent SEMS placement for malignant biliary strictures between January 2018 and March 2023, 30 patients who attempted to undergo prophylactic GBS placement before SEMS placement were included.Results: Technical success was achieved in 21 cases (70.0%). The mean diameter of the cystic duct was more significant in the successful cases (6.5 mm vs. 3.7 mm, p<0.05). Adverse events occurred for 7 patients (23.3%: acute pancreatitis in 7; non-obstructive cholangitis in 1; perforation of the cystic duct in 1 with an overlap), all of which improved with conservative treatment. No patients developed AC when the GBS placement was successful, whereas 25 of the 128 patients (19.5%) without a prophylactic GBS developed AC during the median follow-up period of 357 days (p=0.043). In the multivariable analysis, GBS placement was a significant factor in preventing AC (hazard ratio, 0.61; 95% confidence interval, 0.37–0.99; p=0.045).Conclusions: GBS may contribute to the prevention of AC after SEMS placement for malignant biliary strictures.